Healthcare · Biotechnology
Price
$9.64
Market Cap
$2.1B
Employees
274
Beta
0.90
Avg Volume
3,140,364
CEO
Pravin U. Dugel
Business Description
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Business History
Price Overview
Price at report time · Jul 3, 4:50am (0m ago)
$9.64
Change · Jul 3
+0.17 (+1.80%)
Day Range
$9.41 – $9.74
52-Week Range
$6.23 – $16.44
50-Day MA
$9.15
200-Day MA
$10.38
Volume
1,765,342.00
Right now · live
loading…
Real-time — the change above is the move since the report (over 0m).
Analyst Price Targets
Low
$25.00
Consensus
$28.33
High
$30.00
(14 analysts)
Share Structure
Outstanding
218,960,358.00
Float
184,373,380.00
Free Float
84.2%
High free float
— 84.2% of shares trade freely, ~15.8% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-6.79
Stock Price: $9.64
EPS (Diluted): -1.42
EPS (Diluted): -1.42
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.47
Stock Price: $9.64
Total Equity: $654.31M
Shares: 187,241,483
Total Equity: $654.31M
Shares: 187,241,483
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-5.56
Market Cap: $2.11B
Total Debt: $76.97M
Cash: $737.06M
EBITDA: -$249.78M
Total Debt: $76.97M
Cash: $737.06M
EBITDA: -$249.78M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.6B
Market Cap: $2.11B
Total Debt: $76.97M
Cash: $737.06M
Total Debt: $76.97M
Cash: $737.06M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
43.86
Stock Price: $9.64
Revenue: $51.82M
Shares: 187,241,483
Revenue: $51.82M
Shares: 187,241,483
EV/Sales (Total value vs revenue — works when P/E can't)
API31.18
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
87.3%
Gross Profit: $45.25M
Revenue: $51.82M
Revenue: $51.82M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-521.0%
Operating Income: -$270.02M
Revenue: $51.82M
Revenue: $51.82M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-513.2%
Net Income: -$265.94M
Revenue: $51.82M
Revenue: $51.82M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-64.6%
Net Income: -$265.94M
Total Equity: $654.31M
Total Equity: $654.31M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-43.5%
Operating Income: -$270.02M
Tax Rate: 0.0%
Equity: $654.31M
Total Debt: $76.97M
Cash: $737.06M
Tax Rate: 0.0%
Equity: $654.31M
Total Debt: $76.97M
Cash: $737.06M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
15.39
Current Assets: $782.13M
Current Liabilities: $50.81M
Current Liabilities: $50.81M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.12
Short-Term Debt: $2.82M
Long-Term Debt: $74.15M
Total Debt: $76.97M
Total Equity: $654.31M
Long-Term Debt: $74.15M
Total Debt: $76.97M
Total Equity: $654.31M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.28
Revenue: $51.82M
Shares: 187,241,483
Shares: 187,241,483
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.49
Total Equity: $654.31M
Shares: 187,241,483
Shares: 187,241,483
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.16
Operating CF: -$204.88M
CapEx: -$12.01M
Shares: 187,241,483
CapEx: -$12.01M
Shares: 187,241,483
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $9.64
Stock Price: $9.64
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$265.94M
Net Income: -$265.94M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares OCUL against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $43.5M | $51.5M | $58.4M | $63.7M | $51.8M |
| Cost of Revenue | $4.4M | $4.5M | $5.3M | $5.6M | $6.6M |
| Gross Profit | $39.1M | $47.0M | $53.2M | $58.1M | $45.2M |
| Operating Expenses | $117.2M | $125.6M | $135.5M | $229.9M | $315.4M |
| Operating Income | -$78.0M | -$78.7M | -$82.4M | -$171.8M | -$270.0M |
| Net Income | -$6.6M | -$71.0M | -$80.7M | -$193.5M | -$265.9M |
| EBITDA | $2.5M | -$61.9M | -$66.4M | -$176.1M | -$249.8M |
| EPS | $-1.05 | $-1.04 | $-1.09 | $-1.22 | $-1.42 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $164.2M | $102.3M | $195.8M | $392.1M | $737.1M |
| Total Current Assets | $191.3M | $129.6M | $232.2M | $441.0M | $782.1M |
| Total Assets | $204.9M | $149.3M | $252.1M | $457.9M | $808.1M |
| Current Liabilities | $26.3M | $31.4M | $34.9M | $41.4M | $50.8M |
| Long-Term Debt | $51.4M | $54.0M | $74.9M | $68.5M | $74.2M |
| Total Liabilities | $116.9M | $113.9M | $160.9M | $142.6M | $153.7M |
| Total Equity | $88.0M | $35.4M | $91.1M | $315.3M | $654.3M |
| Retained Earnings | -$545.8M | -$616.8M | -$697.6M | -$891.1M | -$1.2B |
Cash Flow (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$65.6M | -$59.6M | -$70.2M | -$134.7M | -$204.9M |
| Capital Expenditure | -$1.2M | -$3.7M | -$6.1M | -$1.3M | -$12.0M |
| Free Cash Flow | -$66.7M | -$63.3M | -$76.3M | -$136.0M | -$216.9M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$63.9M | -$61.9M | $93.5M | $196.1M | $345.0M |
Analyst Estimates (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$120.4M $76.6M – $244.0M
|
$303.7M $303.7M – $303.7M
|
$693.7M $455.9M – $1.3B
|
$1.0B $671.8M – $1.9B
|
| EBITDA |
-$94.9M -$192.4M – -$60.4M
|
-$239.4M -$239.4M – -$239.4M
|
-$546.8M -$990.0M – -$359.4M
|
-$805.8M -$1.5B – -$529.6M
|
| Net Income |
-$233.0M -$325.6M – -$140.3M
|
-$287.6M -$425.2M – -$65.6M
|
-$1.2M -$2.6M – $-692,145
|
$178.3M $98.8M – $366.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +18.3% | +13.5% | +9.0% | -18.7% |
| Gross Profit Growth | +20.0% | +13.2% | +9.3% | -22.1% |
| Operating Income Growth | -0.8% | -4.7% | -108.5% | -57.2% |
| Net Income Growth | -984.1% | -13.7% | -139.7% | -37.4% |
| EBITDA Growth | -2,538.2% | -7.3% | -165.2% | -41.8% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Dugel Pravin | G-Gift | 50,092.00 | $0.00 | $0 |
| 2026-06-16 | Dugel Pravin | G-Gift | 50,092.00 | $0.00 | $0 |
| 2026-06-10 | Warden Charles M | A-Award | 14,000.00 | $0.00 | $0 |
| 2026-06-10 | Warden Charles M | A-Award | 44,000.00 | $8.74 | $384,560 |
| 2026-06-10 | Graves Adrienne L | A-Award | 14,000.00 | $0.00 | $0 |
| 2026-06-10 | Graves Adrienne L | A-Award | 44,000.00 | $8.74 | $384,560 |
| 2026-06-10 | Robins Jason Shand | A-Award | 15,441.00 | $0.00 | $0 |
| 2026-06-10 | Robins Jason Shand | A-Award | 14,024.00 | $8.74 | $122,570 |
| 2026-06-10 | Hong Seung Suh | A-Award | 14,000.00 | $0.00 | $0 |
| 2026-06-10 | Hong Seung Suh | A-Award | 44,000.00 | $8.74 | $384,560 |
| 2026-06-10 | LINDSTROM RICHARD L MD | A-Award | 14,000.00 | $0.00 | $0 |
| 2026-06-10 | LINDSTROM RICHARD L MD | A-Award | 44,000.00 | $8.74 | $384,560 |
| 2026-06-10 | RAINES MERILEE | A-Award | 14,000.00 | $0.00 | $0 |
| 2026-06-10 | RAINES MERILEE | A-Award | 44,000.00 | $8.74 | $384,560 |
| 2026-06-10 | Williams Leslie J. | A-Award | 14,000.00 | $0.00 | $0 |
| 2026-06-10 | Williams Leslie J. | A-Award | 44,000.00 | $8.74 | $384,560 |
| 2026-06-03 | Waheed Nadia | S-Sale | 14,828.00 | $8.27 | $122,628 |
| 2026-05-26 | Dugel Pravin | S-Sale | 21,156.00 | $8.20 | $173,479 |
| 2026-05-28 | Dugel Pravin | G-Gift | 394,696.00 | $0.00 | $0 |
| 2026-05-28 | Dugel Pravin | G-Gift | 394,696.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for OCUL — it's generated by the pipeline (
market-narrative step).
No community reviews yet for OCUL.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.373 · 697c9e64 · 2026-07-02 20:17:59